Synaptogenix (NASDAQ:TAOX) Releases Earnings Results

by · The Cerbat Gem

Synaptogenix (NASDAQ:TAOX – Get Free Report) released its quarterly earnings data on Thursday. The company reported ($1.83) earnings per share for the quarter, Zacks reports.

Synaptogenix Price Performance

Shares of NASDAQ TAOX remained flat at $3.48 during mid-day trading on Thursday. 103,311 shares of the stock traded hands, compared to its average volume of 90,615. The business has a 50-day moving average of $3.62 and a 200-day moving average of $4.41. The company has a market capitalization of $26.00 million, a P/E ratio of -0.26 and a beta of 1.45. Synaptogenix has a 52-week low of $3.18 and a 52-week high of $10.00.

Wall Street Analysts Forecast Growth

TAOX has been the subject of several analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Synaptogenix in a research note on Friday, July 17th. Wall Street Zen raised Synaptogenix from a “sell” rating to a “hold” rating in a research note on Saturday, May 16th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Synaptogenix presently has an average rating of “Sell”.

Read Our Latest Analysis on TAOX

Synaptogenix Company Profile

(Get Free Report)

Synaptogenix, Inc operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer’s disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc has licensing agreements with Stanford University; Icahn School of Medicine at Mount Sinai; and The Board of Trustees of the Leland Stanford Junior University.

Read More